• Test Code:
    1405
  • Department:
  • Test Synonyms:
    ACAD9ACADLACADMACADSACADVLCPT1ACPT1BCPT2ETFAETFBETFDH GLUD1HADHHADHAHADHBHMGCLHMGCS2HSD17B10LPIN1SLC22A5SLC25A20TAZ
  • CPT Code(s):
    81405x381406x581479x14
Background:

Fatty acid oxidation is a metabolic process allowing for cells to utilize fats as an energy source instead of glucose. Mutations in genes encoding the cellular machinery for fatty acid oxidation can be clinically heterogeneous, but biochemical tests are carried out during newborn screening to assess sets of metabolic markers for fatty acid oxidation deficiency. Patients may present with hypoglycemia, abnormality of liver, cardiomyopathy, and muscle weakness. This next-generation sequencing panel tests the coding regions for 22 genes associated with fatty acid oxidation deficiency.

Reasons for Referral:

  • Abnormality in newborn screening
  • Confirmation of a clinical diagnosis
  • Carrier testing

Methodology:

Next generation sequencing will analyze the exons or coding regions of 22 genes associated with fatty acid oxidation deficiency using Illumina NextSeq 500 technology and preparing samples using hybridization probes to enrich exonic regions.

Fatty Acid Oxidation Deficiency (22 genes): ACAD9, ACADL, ACADM, ACADS, ACADVL, CPT1A, CPT1B, CPT2, ETFA, ETFB, ETFDH, GLUD1, HADH, HADHA, HADHB, HMGCL, HMGCS2, HSD17B10, LPIN1, SLC22A5, SLC25A20, TAZ

Specimen Requirements:

Blood:  EDTA or ACD (Solution A or B):

  • Adult: 5 mL
  • Child: 5 mL
  • Infant: 2-3 mL

A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information, including ethnicity, clinical history, and family history.

Test Performed (Days):

Weekly

Turn Around Time:

8 weeks

Shipment Sensitivity Requirements:

  • Package and ship specimen to remain cold, but not frozen. 
  • Ship via overnight express, using the FedEx priority overnight label provided. 
  • Contact Client Services for shipping kits and instructions at (855) 535-1522.

References:

Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More